Characteristics of CP-CML patients with major-route ACAs
| No acc. to Table 3 . | Trisomy 8 . | Karyotype (short) in addition to t(9;22)(q34;q11) . | Metaphases with ACAs, % . | Complex . | Best response . | Follow-up, y . | Course . | Comments . |
|---|---|---|---|---|---|---|---|---|
| 26 | ider(22) | 44 | CMR4 | 6,9 | No progress | Alive in CMR4 | ||
| 27 | 1 | +8,i(17)(q10),+der(22) | 71 | 1 | none | 1,7 | BC* | SCT after BC |
| 28 | 1 | +8 | 100 | CMR4 | 5,7 | * | Died in remission, no follow-up | |
| 29 | 1 | +8,+8,i(17)(q10),+19,+der(22) | 21 | 1 | none | 6,9 | BC | Alive after SCT |
| 30 | idicder(22) | 88 | CCR | 6,5 | Imatinib failure | Alive after SCT | ||
| 31 | 1 | +8 | 76 | CHR | 7,2 | Alive after SCT | ||
| 32 | -14,i(17)(q10),-18 | 58 | 1 | none | 0,4 | BC* | ||
| 33 | +der(22) | 10 | CHR | 3,2 | Imatinib failure* | SCT | ||
| 34 | 1 | +8 | 8 | CMR4 | 6,1 | No progress | Alive in CMR4 | |
| 35 | 1 | +8 | 60 | none | 2,7 | BC* | ||
| 36 | 1 | +3,+8,+12,+13,+14,+18,+19, +21,+der(22) | 35 | 1 | none | 4,9 | AP | Alive after SCT |
| 37 | +der(22) | 50 | none | 1,3 | Sepsis* | Imatinib failure | ||
| 38 | +der(22) | 100 | CMR4 | 3,0 | CP | Alive in MMR | ||
| 39 | 1 | +8,i(17)(q10) | 69 | 1 | MMR | 3,3 | No progress | Alive in MMR |
| 40 | 1 | +8,i(17)(q10) | 100 | 1 | CMR4 | 3,5 | BC* | SCT after BC |
| 41 | ider(22) | 59 | CHR | 3,8 | * | Aplasia after imatinib failure | ||
| Total | 9 | 6 | 8 patients died |
| No acc. to Table 3 . | Trisomy 8 . | Karyotype (short) in addition to t(9;22)(q34;q11) . | Metaphases with ACAs, % . | Complex . | Best response . | Follow-up, y . | Course . | Comments . |
|---|---|---|---|---|---|---|---|---|
| 26 | ider(22) | 44 | CMR4 | 6,9 | No progress | Alive in CMR4 | ||
| 27 | 1 | +8,i(17)(q10),+der(22) | 71 | 1 | none | 1,7 | BC* | SCT after BC |
| 28 | 1 | +8 | 100 | CMR4 | 5,7 | * | Died in remission, no follow-up | |
| 29 | 1 | +8,+8,i(17)(q10),+19,+der(22) | 21 | 1 | none | 6,9 | BC | Alive after SCT |
| 30 | idicder(22) | 88 | CCR | 6,5 | Imatinib failure | Alive after SCT | ||
| 31 | 1 | +8 | 76 | CHR | 7,2 | Alive after SCT | ||
| 32 | -14,i(17)(q10),-18 | 58 | 1 | none | 0,4 | BC* | ||
| 33 | +der(22) | 10 | CHR | 3,2 | Imatinib failure* | SCT | ||
| 34 | 1 | +8 | 8 | CMR4 | 6,1 | No progress | Alive in CMR4 | |
| 35 | 1 | +8 | 60 | none | 2,7 | BC* | ||
| 36 | 1 | +3,+8,+12,+13,+14,+18,+19, +21,+der(22) | 35 | 1 | none | 4,9 | AP | Alive after SCT |
| 37 | +der(22) | 50 | none | 1,3 | Sepsis* | Imatinib failure | ||
| 38 | +der(22) | 100 | CMR4 | 3,0 | CP | Alive in MMR | ||
| 39 | 1 | +8,i(17)(q10) | 69 | 1 | MMR | 3,3 | No progress | Alive in MMR |
| 40 | 1 | +8,i(17)(q10) | 100 | 1 | CMR4 | 3,5 | BC* | SCT after BC |
| 41 | ider(22) | 59 | CHR | 3,8 | * | Aplasia after imatinib failure | ||
| Total | 9 | 6 | 8 patients died |
ACA indicates additional chromosomal aberrations; SCT, stem cell transplantation; BC, blast crisis; CMR4; complete molecular response; MMR, major molecular remission; AP, accelerated phase; CCR, complete cytogenetic remission; CP, chromic phase; and CHR, complete haematological remission.
Patient died.